Source: Clinical Infectious Diseases. Unidade: FMRP
Subjects: ANTI-HIV (ADMINISTRAÇÃO E DOSAGEM), INFECÇÕES POR HIV (QUIMIOTERAPIA)
ABNT
NACHMAN, Sharon et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-indected children aged 2 through 18 years. Clinical Infectious Diseases, v. 58, n. 3, p. 413-422, 2014Tradução . . Disponível em: https://doi.org/10.1093/cid/cit696. Acesso em: 13 jun. 2024.APA
Nachman, S., Zheng, N., Acosta, E. P., Teppler, H., Homony, B., Graham, B., et al. (2014). Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-indected children aged 2 through 18 years. Clinical Infectious Diseases, 58( 3), 413-422. doi:10.1093/cid/cit696NLM
Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A, Cervi MC. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-indected children aged 2 through 18 years [Internet]. Clinical Infectious Diseases. 2014 ; 58( 3): 413-422.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1093/cid/cit696Vancouver
Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A, Cervi MC. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-indected children aged 2 through 18 years [Internet]. Clinical Infectious Diseases. 2014 ; 58( 3): 413-422.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1093/cid/cit696